Hemodynamically significant patent arterial duct in premature infants can be the reason of life-threatening complications. Thus it is topical to define the high risk of such complications and mortality in early neonatal period. We have reviewed researches results covering prognostic value of natriuretic peptides level in premature infants with hemodynamically significant patent arterial duct. The data on management planning of such patients according to the A-type and B-type natriuretic peptides levels is presented.

Containment, prevention and elimination of infectious disease is the state duty for citizens. Development of the National Immunization Calendar as well as challenges in preventive vaccination system both are significant investment into the future. Advantages of vaccination are not limited only by infection diseases control. Experts of World Health Organization recognize positive influence of immunization on economic. Vaccines give unprecedented opportunities on alleviation of human sufferings but it can be possible only due to perfect work of immunization calendar. It is necessary to estimate our National Immunization Calendar alongside with suggested by World Health Organization and professional associations plans. It is essential to estimate experience and facilities of modern vaccinology. This entailed the optimal preventive vaccination schedule, which can be implemented in the structure of existing national calendar.

Background. Prognosis of therapy results of patients with the juvenile idiopatic arthritis (JIA) without systematic manifestations is the precondition of their treatment efficiency enhancement.

Objective. Our aim was to establish early predictors for remission achievement in patients with JIA without systematic manifestations who received Etanercept therapy.

Methods. In prospective cohort study the therapy results of patients with JIA without systematic manifestations hospitalized from December, 2009 to August, 2014 and administrated with Etanercept are analysed. The association of initial demographic indicators as well as initial and registered after a month of treatment clinical and laboratory indicators with remission achievement after a year of treatment according to the Wallace criteria is estimated.

Results. The research included 197 patients with JIA without systematic manifestations who received Etanercept in 0.4 mg/kg dose twice a week subcutaneously (the maximum single dose — 25 mg). In addition to Etanercept 136 (69%) patients received Methotrexat, 121 (61%) — non-steroidal anti-inflammatory drugs, 10 (5%) — glucocorticosteroids, 6 (3%) — Sulfasalazine. After a year of treatment remission was recorded in 77 out of 197 (39.1%) patients. According to multivariate analysis the remission predictors are the following: tender joint count 4 (odds ratio (OR) 4.38; 95% confidential interval (CI) 2.33–8.55), duration of illness before Etanercept therapy 2 years (OR 1.28; 95% CI 1.02–2.15), disease activity decline according to JADAS71 index 10 points in a month of the therapy including Etanercept (OR 2.59; 95% CI 1.38–5.03). Model sensitivity was 32% (all three criteria in 25/77 patients with remission), specificity — 94% (lack of even one criteria in 113/120 patients who did not achieve remission).

Conclusion. The predictors of remission in patients with JIA without systematic manifestations in 1 year of Etanercept therapy are smaller tender joint count prior to therapy, smaller duration of illness as well as significant disease activity decline in a month of the therapy. 

Fermented milk products have functional properties which are useful for human health. Therefore this product group is frequently recommended for young children nutrition. Though until recently there were concerns among pediatricians about using of adapted acidified formulas instead of non-acidified. Modern data on administration efficiency and safety of adapted acidified formulas with probiotics is discussed, as well as functional effects of such formulas in infants are covered in this review.

The sequence for the development of the multiple case methodology (training technology) for accreditation of health care professionals has been presented. The multidimensionality of cases allows to cover all functions of professional standards. To improve the technique reliability, the multiple-choice tests have been offered. The requirement of local independence of tasks has been implemented. The results of approbation of cases with participation of 114 graduates (6th year) of 5 medical universities have been analysed. The interpretation of the analysis results and their use for assessing the professional readiness of health care professionals have been offered.

Background. Epidermolysis bullosa acquisita (EBA) is chronic disease accompanied with subepidermal blistering on skin and mucous membranes as a result of autoimmune aggression to type VII collagen. EBA diagnostics in children is complicated due to similarity of clinical presentation with other bullous dermatosis in children.

Clinical Case Description. The description of three clinical cases of EBA in children is provided. It is shown that for establishing the diagnosis it is necessary to estimate clinical evidence and to define the depth of blisters according to the results of histological examination of skin biopsy sample. Determination of IgG deposition positions relatively to the skin basal membrane due to performed indirect immunofluorescence test helps us to establish final diagnosis and specify patient management. Medical drug Dapsone was used in children with EBA, it has shown to be effective and safe to use as the first-line drug in management of such patients.

Conclusion. The algorithm for EBA differential diagnosis with other bullous dermatosis in children is provided. Successful results of medical treatment are described.